Our Pricing

Mounjaro Havercroft: Access UK-Licensed Weight Loss Treatment with Expert Clinical Support

Published: 6 October 2026

Residents seeking Mounjaro Havercroft can now access this clinically proven weight loss treatment through Cured Pharmacy, a UK-registered online service offering genuine tirzepatide injections from £124.99. Our GPhC-registered clinical team provides free online consultations under three minutes, with discreet delivery directly to your Havercroft address. All prescriptions are issued by UK-registered prescribers following comprehensive clinical assessment, ensuring safe and compliant access to this MHRA-licensed medication.

How Mounjaro Havercroft Service Works Through Cured Pharmacy

Accessing Mounjaro Havercroft through our online pharmacy streamlines the prescription process while maintaining the highest clinical standards. Our service begins with a confidential online consultation where you complete a detailed medical questionnaire reviewed by a UK-registered prescriber. This assessment evaluates your suitability for tirzepatide treatment, considering your weight loss goals, medical history, current medications, and any contraindications [1].

Once approved, your Mounjaro prescription is dispensed by our GPhC-registered pharmacy team under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073). We dispatch your medication in 100% discreet packaging with tracked delivery to Havercroft, typically arriving within 1-3 working days. Our transparent pricing model shows costs upfront—£124.99 for Mounjaro—before you complete your consultation, with an additional £20 off your first order using code Weightlossnew.

Ongoing clinical support is integral to our Mounjaro Havercroft service. Our prescribers monitor your progress through follow-up assessments, adjusting dosages according to the standard titration schedule used in clinical trials. This graduated approach begins at 2.5mg weekly, increasing every four weeks to optimise efficacy while minimising gastrointestinal side effects commonly experienced during initial treatment phases [2].

Clinical Efficacy of Mounjaro Havercroft Patients Can Expect

Mounjaro Havercroft patients benefit from the same clinically proven weight loss outcomes demonstrated in the landmark SURPASS clinical trial programme. In the SURPASS-2 trial, participants receiving the maximum 15mg tirzepatide dose achieved an average weight reduction of 12.4kg over 40 weeks, compared to 6.2kg with semaglutide 1mg [3]. These results position tirzepatide as one of the most effective pharmacological interventions currently available for weight management.

The dual mechanism of action distinguishes Mounjaro from single-agonist GLP-1 medications. Tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, producing enhanced effects on appetite suppression, gastric emptying, and insulin sensitivity [4]. This dual agonism explains why clinical trials consistently show superior weight loss outcomes compared to GLP-1-only treatments.

Weight Loss Timeline for Mounjaro Havercroft Users

Patients typically notice initial weight changes within the first four weeks of Mounjaro Havercroft treatment, though optimal results require consistent use over several months. The SURPASS trials documented progressive weight reduction throughout the 40-72 week study periods, with most participants achieving their maximum weight loss between weeks 36-52 [3]. Individual results vary based on adherence to the prescribed regimen, dietary modifications, physical activity levels, and metabolic factors.

Mounjaro Havercroft Dosing and Administration Guidance

Our Mounjaro Havercroft prescribers follow the MHRA-approved titration schedule to balance efficacy with tolerability. Treatment begins with a 2.5mg subcutaneous injection once weekly for four weeks, serving as an initial dose to allow your body to adapt to the medication. This is followed by an increase to 5mg weekly for four weeks, then 7.5mg, 10mg, 12.5mg, and finally the maintenance dose of 15mg, with each increment occurring at four-week intervals [1].

The KwikPen delivery system supplied in your Mounjaro Havercroft prescription simplifies self-administration. Each pre-filled pen contains four weekly doses and features an easy-to-use injection mechanism requiring no manual needle attachment. Injection sites include the abdomen (avoiding the area around the navel), thigh, or upper arm, with site rotation recommended to prevent lipodystrophy. Injections can be administered at any time of day, with or without meals, though maintaining a consistent weekly schedule optimises therapeutic effects.

Storage Requirements for Mounjaro Havercroft Deliveries

Upon receiving your Mounjaro Havercroft delivery, store unused pens in a refrigerator at 2-8°C, protected from light. Once in use, a pen may be kept at room temperature (up to 30°C) for up to 21 days, providing flexibility for patients who travel or prefer not to inject cold medication. Never freeze tirzepatide, and discard any pens that have been frozen, as this compromises the medication's molecular structure and efficacy.

Safety Profile and Side Effects of Mounjaro Havercroft Treatment

The most commonly reported side effects among Mounjaro Havercroft users mirror those documented in clinical trials, predominantly affecting the gastrointestinal system. Nausea, diarrhoea, vomiting, constipation, and abdominal discomfort occur most frequently during dose escalation phases, typically diminishing as treatment continues [2]. These effects are generally mild to moderate in severity and resolve without intervention, though our prescribers can recommend management strategies including dietary adjustments and anti-nausea medications if needed.

Serious adverse events require immediate medical attention and include symptoms of pancreatitis (severe persistent abdominal pain radiating to the back), signs of thyroid tumours (lump in the neck, difficulty swallowing, persistent hoarseness), severe allergic reactions, and diabetic retinopathy complications in patients with pre-existing diabetes. Our Mounjaro Havercroft service includes comprehensive safety screening during your initial consultation to identify contraindications such as personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [4].

Who Can Access Mounjaro Havercroft Prescriptions

Mounjaro Havercroft prescriptions are issued to adults (18 years and older) with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia. Our prescribers assess eligibility based on MHRA licensing criteria and NICE guidance for weight management interventions, ensuring appropriate patient selection [1].

Certain medical conditions preclude Mounjaro Havercroft treatment. Absolute contraindications include pregnancy or planned pregnancy (tirzepatide may harm foetal development), breastfeeding, personal or family history of medullary thyroid carcinoma, and Multiple Endocrine Neoplasia syndrome type 2. Relative contraindications requiring careful prescriber evaluation include severe gastrointestinal disease, history of pancreatitis, severe renal impairment, and diabetic retinopathy. Our consultation process thoroughly evaluates these factors to ensure patient safety.

Mounjaro Havercroft for Non-Diabetic Weight Loss

While originally developed for type 2 diabetes management, Mounjaro is increasingly prescribed off-label for weight loss in non-diabetic patients through services like our Mounjaro Havercroft programme. The SURMOUNT-1 trial specifically evaluated tirzepatide in adults without diabetes, demonstrating average weight reductions of 15-20.9% depending on dose, with 89% of participants on the 15mg dose achieving at least 5% weight loss [3]. UK prescribers can legally prescribe licensed medications off-label when clinically justified, as is common practice for weight management pharmacotherapy.

Why Choose Cured Pharmacy for Mounjaro Havercroft Access

Our Mounjaro Havercroft service distinguishes itself through transparent upfront pricing, eliminating the hidden costs and subscription fees common with other online providers. At £124.99 per month, you see the exact cost before completing your consultation, with an additional £20 discount on your first order using code Weightlossnew. This price includes the clinical consultation, prescription, medication, and discreet delivery to your Havercroft address—no surprise charges or mandatory ongoing subscriptions.

As a fully registered UK pharmacy (GPhC 9012511) operating under Superintendent Pharmacist Tarun Kumar's oversight, we supply only genuine UK-licensed Mounjaro sourced through legitimate pharmaceutical supply chains. Every prescription undergoes review by our qualified clinical team, with ongoing monitoring to track your progress and adjust treatment as needed. Our three-minute online consultation provides the same clinical rigour as in-person GP appointments while offering the convenience of accessing care from your Havercroft home.

We guarantee the lowest Mounjaro prices in the UK, backed by our price-match commitment. If you find a lower price from another registered UK pharmacy, we'll match it. Combined with our fast dispatch (orders placed before 3pm are processed same-day), tracked delivery, and responsive patient support team available via phone at (+44) 116 4646009, our Mounjaro Havercroft service provides comprehensive, convenient, and cost-effective access to this transformative weight loss treatment.

Scientific References

1. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk. [accessed 6 October 2026]
2. Dahl, D., Onishi, Y., Norwood, P., et al. (2022). Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 randomized clinical trial. JAMA, 327(6), 534-545. [accessed 6 October 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 6 October 2026]
4. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 6 October 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 6 October 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 6 October 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 6 October 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.